Clinical Trial

A Phase I Study of JSKN021 in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-31
notable Trial sites expanded: 0 -> 6 locations 2026-07-31
Trial Details
NCT Number NCT07617727
Lead Sponsor Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Conditions Advanced Malignant Solid Tumors
Enrollment 199 participants
Start Date 2026-06-02
Primary Completion 2028-10-31 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30